세계의 HPV 검사 및 PAP 검사 시장 : 제품 및 서비스별, 검사 유형별, 기술별, 용도별, 케어 환경별 예측(-2030년)

The HPV testing and Pap test market is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0% during the forecast period. The rising awareness of cervical cancer and the importance of timely screening is significantly boosting the HPV testing and Pap test market.

Public health campaigns, government screening initiatives, and educational efforts are making women more informed about the risks associated with HPV infection and the critical role of early detection. This heightened awareness is leading to greater participation in routine screening programs, directly fueling the demand for both HPV and Pap tests. Support from healthcare providers, advocacy groups, and non-profit organizations further reinforces preventive screening as a key component of women's healthcare. As more women gain access to information and resources about screening, test volumes are expected to rise steadily, driving sustained market growth and strengthening the role of HPV and Pap testing in reducing cervical cancer incidence worldwide.

"By product & service, the consumables segment dominated the HPV testing and Pap test market in 2024."

Based on product & service, the HPV testing and Pap test market is segmented into consumables, instruments, and services. In 2024, consumables accounted for the largest share of the market. This dominance is driven by the widespread use of reagents, collection kits, and assay consumables that are essential for both HPV and Pap testing on a recurring basis. The increasing adoption of HPV screening programs, coupled with the expansion of cervical cancer prevention initiatives, has created steady demand for these products. Consumables play a critical role in ensuring accuracy and reproducibility of test results, which is reinforced by regulatory guidelines that mandate standardized testing protocols. Moreover, the growing shift toward molecular-based HPV assays and automated cytology platforms has further increased the reliance on specialized consumables. The recurring nature of consumable usage, compared to one-time investments in instruments, positions this segment as the largest revenue contributor in the HPV testing and Pap test market.

"By application, the vaginal cancer screening segment is projected to achieve the highest growth during the forecast period."

By application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. While cervical cancer screening currently accounts for the majority of testing volumes due to its high prevalence and established screening guidelines, vaginal cancer screening is expected to witness the fastest growth during the forecast period. This growth is primarily driven by increasing awareness of vaginal cancers, improvements in diagnostic sensitivity of HPV tests, and a gradual expansion of screening practices beyond cervical cancer. Rising research efforts and clinical recommendations supporting HPV testing for broader gynecologic cancer detection are also contributing to the adoption of vaginal cancer screening. Although it remains a relatively smaller segment today, the potential for early detection and improved patient outcomes is likely to accelerate demand, positioning vaginal cancer screening as a key growth area in the HPV testing and Pap test market.

"The Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

The market for HPV testing and Pap tests is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the fastest growth in the HPV testing and Pap test market during the forecast period. Rapid urbanization, improving healthcare infrastructure, and increasing access to diagnostic facilities are expanding screening opportunities across the region. Government-led initiatives and public health campaigns in countries such as China, India, and Southeast Asian nations are actively promoting cervical cancer awareness and early detection programs. The rising prevalence of HPV infections and growing concerns about women's health are driving the adoption of HPV and Pap testing. Additionally, market players are introducing cost-effective and high-throughput testing solutions tailored to local needs, further accelerating adoption. The combination of expanding healthcare access, regulatory support, and rising patient awareness positions the Asia Pacific as the fastest-growing regional segment in the global HPV testing and Pap test market.

Breakdown of the profiles of primary participants in the HPV testing and Pap test market:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Director-level Executives (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, Inc. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China).

Research Coverage:

This research report categorizes the HPV testing and Pap test market by product & service (consumables, instruments, and services), test type [HPV testing (primary HPV testing, co-testing, and follow-up HPV testing) and Pap tests], technology (molecular diagnostics, immunodiagnostics, and cytology), application (cervical cancer screening and vaginal cancer screening), care setting (hospitals, diagnostic laboratories, and physicians' offices & clinics), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the HPV testing and Pap test market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. Competitive analysis of upcoming startups in the HPV testing and Pap test market ecosystem is covered in this report.

Reasons to buy this report:

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising HPV cases and subsequent increase in cervical cancer, growing awareness of cervical cancer screening programs, and increasing R&D funding initiatives on cervical cancer prevention), opportunities (regulatory guidelines for cervical cancer screening and innovative improvements in HPV tests), restraints (growing awareness of HPV vaccinations), and challenges (uncertain reimbursement scenario, stringent regulatory & legal requirements, and operational barriers) influencing the growth of the HPV testing and Pap test market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches/approvals in the HPV testing and Pap test market.
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), and Danaher Corporation (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
    • 2.3.1.5 Epidemiology-based test volume estimation approach
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW
• 4.2 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
• 4.3 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030
• 4.4 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030
• 4.5 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030
• 4.6 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030
• 4.7 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
    • 5.2.1.2 Growing awareness about cervical cancer screening programs
    • 5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Growing awareness and adoption of HPV vaccination
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Regulatory guidelines for cervical cancer screening
    • 5.2.3.2 Innovative improvements in HPV tests
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Uncertain reimbursement scenario
    • 5.2.4.2 Stringent regulatory and legal requirements
    • 5.2.4.3 Operational barriers
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF HPV AND PAP TESTS
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Molecular diagnostics
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Cytology
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Immunodiagnostics
• 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 IMPORT DATA FOR HS CODE 3822
  • 5.12.2 EXPORT DATA FOR HS CODE 3822
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: UTILIZATION OF HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN THAILAND
  • 5.13.2 CASE STUDY 2: IMPLEMENTATION OF HUMAN PAPILLOMAVIRUS PRIMARY SCREENING OF CERVICAL CANCER IN BRITISH COLUMBIA
  • 5.13.3 CASE STUDY 3: COMPARATIVE EVALUATION OF HPV SELF-SAMPLING IN INDIA
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY FRAMEWORK
    • 5.14.1.1 NORTH AMERICA
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 Germany
      • 5.14.1.2.2 UK
      • 5.14.1.2.3 France
      • 5.14.1.2.4 Italy
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
      • 5.14.1.4.1 Brazil
      • 5.14.1.4.2 Mexico
    • 5.14.1.5 Middle East
    • 5.14.1.6 Africa
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF BUYERS
  • 5.15.2 BARGAINING POWER OF SUPPLIERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 IMPACT OF AI/GENERATIVE AI ON HPV TESTING AND PAP TEST MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI
  • 5.17.5 FUTURE OF AI IN HPV TESTING AND PAP TEST MARKET
• 5.18 IMPACT OF 2025 US TARIFFS ON HPV TESTING AND PAP TEST MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals
    • 5.18.5.2 Diagnostic laboratories
    • 5.18.5.3 Physicians' offices & clinics

6 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
• 6.3 INSTRUMENTS
  • 6.3.1 INCREASING ADOPTION OF AUTOMATED DIAGNOSTIC SYSTEMS TO DRIVE GROWTH
• 6.4 SERVICES
  • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND

7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 HPV TESTING
  • 7.2.1 PRIMARY HPV TESTING
    • 7.2.1.1 Test sensitivity and accuracy to drive growth
  • 7.2.2 FOLLOW-UP HPV TESTING
    • 7.2.2.1 Irregular Pap test results to drive adoption
  • 7.2.3 CO-TESTING
    • 7.2.3.1 Co-testing to drive rapid detection results for cervical cancer
• 7.3 PAP TESTS
  • 7.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET

8 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 MOLECULAR DIAGNOSTICS
  • 8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN HPV DETECTION TO DRIVE MARKET GROWTH
• 8.3 IMMUNODIAGNOSTICS
  • 8.3.1 COST BENEFITS OF IMMUNOASSAYS TO BOOST DEMAND
• 8.4 CYTOLOGY
  • 8.4.1 AUTOMATION AND DIGITAL IMAGING TO DRIVE ADOPTION

9 HPV TESTING AND PAP TEST MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CERVICAL CANCER SCREENING
  • 9.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
• 9.3 VAGINAL CANCER SCREENING
  • 9.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET

10 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
• 10.3 DIAGNOSTIC LABORATORIES
  • 10.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
• 10.4 PHYSICIANS' OFFICES & CLINICS
  • 10.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH

11 HPV TESTING AND PAP TEST MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising government initiatives for cervical cancer testing to expedite growth
  • 11.2.3 CANADA
    • 11.2.3.1 Growing awareness of cervical cancer screening to support growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Established healthcare infrastructure and rising healthcare spending to promote growth
  • 11.3.3 UK
    • 11.3.3.1 Rising focus on research projects for specific cancers to contribute to growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High incidence of cervical cancer and associated investments in genomics to stimulate growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to boost market
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing research on cancer diagnostics to accelerate growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Growing public access to modern healthcare to propel market
  • 11.4.3 JAPAN
    • 11.4.3.1 Rising demand for technologically advanced cervical cancer screening tests to facilitate growth
  • 11.4.4 INDIA
    • 11.4.4.1 Expanding healthcare access and high cervical cancer burden to drive market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Universal healthcare access to speed up growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Improved access to healthcare to sustain growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 SAUDI ARABIA
    • 11.6.2.1 Rising government healthcare expenditure to augment growth
  • 11.6.3 UAE
    • 11.6.3.1 Increasing emphasis on healthy lifestyles and quality of life to encourage growth
  • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.5.1 COMPANY VALUATION
  • 12.5.2 FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product & service footprint
    • 12.7.5.4 Test type footprint
    • 12.7.5.5 Technology footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 HOLOGIC, INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Right to win
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses and competitive threats
  • 13.1.2 BECTON, DICKINSON AND COMPANY (BD)
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 QIAGEN
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 DANAHER CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses and competitive threats
  • 13.1.6 ABBOTT
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 SEEGENE INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches and approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 SD BIOSENSOR, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 SANSURE BIOTECH INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 ACON LABORATORIES, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MOLBIO DIAGNOSTICS LIMITED
  • 13.2.2 AB ANALITICA S.R.L.
  • 13.2.3 CERTEST BIOTEC
  • 13.2.4 ATILA BIOSYSTEMS
  • 13.2.5 TELLGEN CORPORATION
  • 13.2.6 DAAN GENE CO., LTD.
  • 13.2.7 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
  • 13.2.8 ANATOLIA GENEWORKS
  • 13.2.9 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
  • 13.2.10 XIAMEN ZEESAN BIOTECH CO., LTD.
  • 13.2.11 ADVANCED MOLECULAR DIAGNOSTICS (AMD)
  • 13.2.12 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
  • 13.2.13 SACACE BIOTECHNOLOGIES SRL
  • 13.2.14 JIANGSU MOLE BIOSCIENCE CO., LTD.
  • 13.2.15 HANGZHOU ALLTEST BIOTECH CO., LTD.
  • 13.2.16 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.
  • 13.2.17 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS